In addition, AZD1480, a potent and competitive JAK1/2 inhibitor, was investigated as a strategy to inhibit the JAK/STAT3 pathway, finally improving the caspase-3-mediated apoptosis of MM cells. Here, STAT3 is linked to Miyoshi myopathy.